Approval of Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026

Pat Growth 25pctExceptional ItemEbitda Margin CompressionResults View source PDF Explain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹780.00

prior close

₹801.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-0.4% vs market

Pharmaceuticals & Biotechnology peers, median of 162sector · industry level+0.3%-0.4% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+1.0

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.4-0.4+0.3-0.4

Next day

-1.3+0.5-1.8+0.7-2.0

-0.5+0.6-1.1+0.4-1.0

-2.2+1.4-3.7+1.7-3.9

-1.3+1.9-3.1+1.8-3.1

-3.0+2.3-5.3+2.0-5.0

-3.8-0.5-3.4+1.3-5.1

15d

+0.0-2.9+2.9-0.6+0.6

-1.7+3.1-4.8+3.8-5.4

+1.2+3.2-2.0+7.8-6.6

+12.2+4.5+7.6+8.2+3.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences reported strong FY2026 results with consolidated revenue from operations of Rs 2,120 crore, up 15% from Rs 1,845 crore in FY2025. Consolidated Profit After Tax grew 31% to Rs 592 crore from Rs 451 crore the prior year. The company received an unmodified (clean) audit opinion from K.P. Rao & Co. on both standalone and consolidated financials. The board recommended a final dividend of Rs 2 per share, subject to shareholder approval. Exceptional items of Rs 240 crore (standalone) and Rs 244 crore (consolidated) were recorded due to provisioning for new Indian Labour Codes. The company listed on NSE and BSE in July 2025 via an IPO.

Likely market impact

The 31% PAT growth and clean audit signal financial health. However, EBITDA margins compressed as total expenses grew faster than revenue, which investors should monitor. The ESOP allotment of 14.8 lakh shares adds to equity dilution.